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a b s t r a c t
Clinical pharmacokinetic studies of ciproﬂoxacin require accurate and precise measurement of plasma
drug concentrations. We describe a rapid, selective and sensitive HPLC method coupled with ﬂuores-
cence detection for determination of ciproﬂoxacin in human plasma. Internal standard (IS; saraﬂoxacin)
was added to plasma aliquots (200L) prior to protein precipitation with acetonitrile. Ciproﬂoxacin
and IS were eluted on a Synergi Max-RP analytical column (150mm×4.6mm i.d., 5m particle
size) maintained at 40 ◦C. The mobile phase comprised a mixture of aqueous orthophosphoric acid
(0.025M)/methanol/acetonitrile (75/13/12%, v/v/v); the pH was adjusted to 3.0 with triethylamine. A
ﬂuorescence detector (excitation/emission wavelength of 278/450nm) was used. Retention times for
ciproﬂoxacin and IS were approximately 3.6 and 7.0min, respectively. Calibration curves of ciproﬂoxacin
were linear over the concentration rangeof 0.02–4g/mL,with correlation coefﬁcients (r2)≥0.998. Intra-
and inter-assay relative standarddeviations (SD)were<8.0%andaccuracyvalues ranged from93% to105%
for quality control samples (0.2, 1.8 and 3.6g/mL). Themean (SD) extraction recoveries for ciproﬂoxacin
from spiked plasma at 0.08, 1.8 and 3.6g/mL were 72.8±12.5% (n=5), 83.5±5.2% and 77.7±2.0%,
respectively (n=8 in both cases). The recovery for IS was 94.5±7.9% (n=15). The limits of detection and
quantiﬁcation were 10ng/mL and 20ng/mL, respectively. Ciproﬂoxacin was stable in plasma for at least
one month when stored at −15 ◦C to −25 ◦C and −70 ◦C to −90 ◦C. This method was successfully applied
oxac
.
 to measure plasma ciproﬂ
in malnourished children
. Introduction
Ciproﬂoxacin is a ﬂuoroquinolone antibiotic that is being
ncreasingly used in children with suspected Gram-negative
nfection. It exhibits a broad-spectrum activity against both
ram-positive and Gram-negative bacteria [1]. In general, ﬂuoro-
uinolones exhibit concentration-dependentbacteriocidal activity,
hich depends on the ratio ofmaximumdrug concentration (Cmax)ominimuminhibitory concentration (MIC) [2]. The ratioof thearea
nder the concentration–time curve from zero to 24h (AUC0–24h)
f ﬂuoroquinolones to MIC is the most important predictor of
linical cure [3]. Satisfactory AUC can be achieved by oral admin-
∗ Corresponding author. Tel.: +254 041 7522535/7522063/7525043;
ax: +254 041 7522390.
E-mail address: sndirangu@kiliﬁ.kemri-wellcome.org (S.N. Muchohi).
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Open access under CC BY license. in concentrations in a population pharmacokinetics study of ciproﬂoxacin
© 2010 Elsevier B.V. 
istration as the drug is rapidly absorbed in children without cystic
ﬁbrosis [4]. Oral absorptionof ciproﬂoxacin, however, canbe signif-
icantly reduced by concomitant administration of milk and foods
containing divalent and trivalent cations, such as Ca2+ and Al3+
[5–7]. Ciproﬂoxacin–food interactions may result in changes both
in the rate and extent of absorption [8] and potentially lead to sub-
therapeutic concentrations of ciproﬂoxacin and therapeutic failure.
Little is known about the pharmacokinetics of oral ciproﬂoxacin
in infants and children and there are no data on the pharmacoki-
netics of ciproﬂoxacin in children with severe malnutrition. The
outcome of African children hospitalised with severe and compli-
cated malnutrition remains poor with many centres reporting high
Open access under CC BY license.case fatality rates [9,10]. Invasive bacterial infection complicates
up to 25% of fatalities with Gram-negative septicaemia, constitut-
ingbetween48and55%of invasivebacterial pathogens [10]. For the
treatment of bacterial infection complicating severe malnutrition
the use of oral formulations of effective antimicrobial treatments
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re attractive since they are both practical and affordable. It has
een demonstrated in critically ill patients that the pharmacoki-
etics of ciproﬂoxacin exhibit large inter-individual variability
11,12]. Children with severe malnutrition present to hospital
ith a range of complications and co-morbid infections includ-
ng HIV/AIDS, invasive bacteria infection and malaria which render
hem severely ill [13]. Clinical studies investigating the pharma-
okinetics of ciproﬂoxacin children with severe and complicated
alnutrition are urgently needed since the pharmacokinetic pro-
esses (absorption, distribution, metabolism and excretion) may
e altered due to associated pathophysiological changes, necessi-
ating rational dosage adjustment of antibiotics. Determination of
lasma ciproﬂoxacin concentrations in vivo is a valuable pharma-
ological tool in optimizing drug dosage regimens. Therefore, there
s a need to develop and validate a suitable bioanalytical method
or measurement of ciproﬂoxacin concentrations in malnourished
hildren to support clinical pharmacokinetic studies.
Various bioanalytical methods used to measure ciproﬂoxacin
oncentrations in biological matrices have been reported. They
nclude capillary electrophoresis [14], spectrophotometry [15,16]
ndhigh-performance liquid chromatography (HPLC) coupledwith
ltraviolet (UV) [17–25], ﬂuorescence [26–35], andbothUVandﬂu-
rescence [36,27] detection. Recently, HPLC methods coupled with
ass spectrometry (LCMS) for determination of ciproﬂoxacin in
uman plasma [27,38] have also been published.
However, most of these techniques have various limitations.
lthoughLCMSoffers excellent selectivity andsensitivity and faster
nalysis time than HPLC methods, it requires relatively expen-
ive instrumentation and highly skilled technical expertise. These
ay not be readily available and/or affordable for most labora-
ories in resource-limited settings. In such settings, selective and
ensitive HPLC methods are preferable to more expensive LCMS
echniques. Moreover, some of the published methods involve
engthy, time-consuming and laborious sample pretreatment and
lean-up procedures, including the use of expensive solid phase
xtraction (SPE) cartridges [16,34] and long chromatographic run
imes (≥10min) [17,19,21,31,32,34,37,39,40]. In addition, some of
he reported methods involve the use of large volumes (≥1000L)
f plasma/serum samples [17,18,32,35,39] rendering them unsuit-
ble for repeat sampling in children where blood sample volume
ust be kept to a minimum. Sample clean-up procedures often
nvolve multiple extraction steps. Thus, the use of an internal
tandard (IS) is crucial to account for any loss of analyte. How-
ver, some of the reported methods do not include the use of
n IS in the sample clean-up procedures, or involve addition of
S after sample extraction [20]. This may lead to variability in
xtraction recovery and consequently, inconsistent pharmacoki-
etic data. Ciproﬂoxacin displays strong ﬂuorescence properties
nd thus more readily detected using a ﬂuorescence detector with-
ut the need for lengthy derivatization procedures.
The aim of this study was to develop and validate a simple,
elective and sensitive reverse-phase HPLC method coupled with
uorescence detection for the determination of ciproﬂoxacin in
mall volumes (200L) of human plasma. The validated method
as successfully applied to a population pharmacokinetics study
f oral ciproﬂoxacin (10mg/kg) in children admitted to hospital
ith severe malnutrition.
. Experimental.1. Chemicals and reagents
Ciproﬂoxacin (Ciprobay®; batch no. 1396107; purity≥98%)
as purchased from Sigma–Aldrich Chemie GmbH (Steinheim,
ermany). Saraﬂoxacin hydrochloride trihydrate (VETRANAL®;gr. B 879 (2011) 146–152 147
batch no. 7204X; purity 97.2%; used as the IS) was bought from
Riedel-de Häen (Sigma–Aldrich Laborochemikalien GmbH; Stein-
heim, Germany). Acetonitrile (HPLC-grade) was purchased from
Fisher Scientiﬁc (Loughborough, Leiceistershire, UK). Methanol
(CHROMASOLV® grade) was obtained from Sigma–Aldrich Chemie
GmbH (Steinheim, Germany). Orthophosphoric acid (85%) and
triethylamine (both HPLC grade) were bought from BDH Labora-
tory Supplies (Poole, UK). Deionised water was prepared in-house
using a commercially available water puriﬁcation system (Pur1te
SelectTM NCP; Pur1te Ltd., Oxford, UK). Drug-free human plasma
was obtained from theNational Blood Transfusion Service (Nairobi,
Kenya).
2.2. Equipment
Chromatography was performed using a SpectraSystemTM HPLC
system (Thermo Separation Products, San Jose, CA, USA), equipped
with a binary gradient pump (P2000), a dual monochromator ﬂuo-
rescence detector (FL3000), and a vacuum degasser (SCM100). A
Rheodyne® manual syringe-loading valve injector (model 7125;
Cotati, CA,USA)ﬁttedwith a50L loopwasused. Chromatographic
peaks were recorded on a data integrator (ChromJet CH-1; Thermo
Separation Products, San Jose, CA, USA). Column temperature was
maintained at 40 ◦C using a column heater controller (model 7990;
Jones Chromatography Ltd., Wales, UK).
2.3. Chromatography
Chromatographic separations were performed on a Synergi®
Max-RP analytical column (150mm×4.6mm i.d., 4m particle
size; Phenomenex Inc., Macclesﬁeld, Cheshire, UK), protected by
a guard column (LiChroSpher® 100 RP-18e, 10mm×4.6mm i.d.,
5m particle size; Merck, Darmstadt, Germany), maintained at
40 ◦C, using a thermostatically controlled column heater. The
mobile phase comprised a mixture of aqueous orthophosphoric
acid (0.025M)/methanol/acetonitrile (75/13/12%, v/v/v) and the
pH was adjusted to 3.0 with triethylamine. The ﬂow rate was set
at 1.0mL/min. The mobile phase was degassed by ultrasonication
prior to use. The ﬂuorescence detection wavelengths were set at
278nm (excitation) and 450nm (emission).
2.4. Preparation of standard solutions
A stock standard solution (1mg/mL) of ciproﬂoxacin was pre-
pared in 0.2M hydrochloric acid (HCl). Working standard solutions
(100 and 10g/mL) were prepared by serial dilution of the stock
standard solution with 0.2M HCl. A stock solution (1mg/mL of the
free base) of saraﬂoxacin (IS) was prepared by accurately weigh-
ing an appropriate amount of saraﬂoxacinhydrochloride trihydrate
and dissolving it in methanol. Working standard solutions (100,
10 and 1g/mL) were prepared by making appropriate serial dilu-
tions of the IS stock solution in methanol. The standard solutions
were stored at−15 ◦C to−25 ◦C, protected from light andwere used
within one month.
2.5. Preparation of calibration standards and quality control
samples
Quality control (QC) samples were independently prepared by
spiking drug-free plasma with various amounts of ciproﬂoxacin to
give ciproﬂoxacin concentrations corresponding to the low (LQC;
0.2g/mL), medium (MQC; 1.8g/mL) and high (HQC; 3.6g/mL)
levels of the calibration curve. Aliquots (500L) of the QC samples
were stored at −70 ◦C to −90 ◦C until analysis, and were thawed to
room temperature before being analyzed together with the patient
plasma samples.
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.6. Sample preparation
Ciproﬂoxacin and IS were extracted from plasma using protein
recipitationbasedon apublishedmethodbyDeSmet et al. [37]. To
ach aliquot (200L) of plasma (calibration standards, QC samples
r patient samples) in a 10mL glass tube, was added the IS (200ng;
0L of 10ng/L saraﬂoxacin) solutionmade up inmethanol. Ace-
onitrile (2mL) was then added to precipitate the plasma proteins.
he samplesweremixedbyvortexing (2min), and then centrifuged
4000 rpm for 10min at 4 ◦C). The upper organic layer was trans-
erred into a clean glass tube and evaporated to dryness in a water
ath (40 ◦C) under a gentle stream of white spot nitrogen gas (BOC
enya Limited, Nairobi, Kenya). The residue was reconstituted in
obile phase (100L), mixed by vortexing, and an aliquot (50L)
njected onto the HPLC column.
.7. Method validation
Method validation was carried out according to the USA Food
nd Drug Administration (FDA) bioanalytical method validation
uidelines [41]. The HPLC ﬂuorescence method was validated for
electivity, sensitivity, linearity, precision and accuracy, recovery,
nd stability.
.7.1. Selectivity
Selectivity of the assay method was assessed by evaluating
otential interference from endogenous compounds and other
rugs which are routinely co-administered with ciproﬂoxacin. Six
andomly selected blank plasma samples were analyzed under
he optimized chromatographic conditions described. The separa-
ion of ciproﬂoxacin and IS and probable endogenous compounds
rom plasma were checked by comparing the chromatograms of
C samples with that of drug-free blank plasma, in order to eval-
ate interference at the retention times of ciproﬂoxacin or IS. In
ddition, interference of drugs that are frequently co-administered
ith ciproﬂoxacin was tested, including paracetamol and chlo-
amphenicol. These drugs were spiked in blank plasma samples
t therapeutic concentrations of each drug. The samples were
xtracted and analyzed as described in Section 2.6. The peak and
he retention time for each drug under the chromatographic condi-
ionsof the ciproﬂoxacin assaywere recorded to assesswhether the
eak for co-administered drug co-eluted with that of ciproﬂoxacin
r the IS.
.7.2. Limit of detection (LOD) and lower limit of quantiﬁcation
LLOQ)
In order to estimate the LOD and LLOQ for the assay, drug-
ree plasma sample was extracted and six replicates were injected
nd analyzed according to the optimized chromatographic condi-
ions. Further drug spiked plasma samples were injected. The LOD
as deﬁned as the lowest concentration of ciproﬂoxacin in spiked
lasma, which produced a peak with as a signal-to-baseline noise
S/N) ratio of ≥3, using a using a 200L plasma sample. The LLOQ
as deﬁned as the lowest concentration on the calibration curve
hich produced a peak with a S/N ratio of ≥10.
.7.3. Linearity of calibration curves
Calibration curves for ciproﬂoxacinwere constructed using nine
alibrators over a concentration range of 0.02–4.0g/mL (i.e., 0.02,
.05, 0.1, 0.2, 0.5, 1.0, 2.0, 3.0 and 4.0g/mL). To a plasma sam-
le aliquot (200L) of each calibration standard in a 10mL glass
ube was added IS (200ng). The samples were assayed using the
ethod described in Section 2.6. Thirteen calibration curves con-
tructed on separate days were analyzed to evaluate the linearity
f the calibration curves. Peak area ratios (ciproﬂoxacin/IS) weregr. B 879 (2011) 146–152
plotted against the corresponding ciproﬂoxacin nominal concen-
trations. Least-squares linear regression analysis of the calibration
data was performed using the linear equation Y=mX+ c; where Y is
the ciproﬂoxacin/IS peak area ratio, X is the ciproﬂoxacin concen-
tration, and m and c are the slope and intercept of the calibration
curve. The linearity of each calibration curve was evaluated from
the slope, intercept and correlation coefﬁcient (r2) of each curve.
Unknown ciproﬂoxacin concentrations were calculated by inter-
polation using the linear regression equation.
2.7.4. Precision and accuracy
The precision and accuracy of the method were evaluated
by analysing the QC samples at three different concentrations
described in Section 2.5. The intra-assay (within-day) precision
and accuracy of the method were evaluated by analysing plasma
aliquots of each QC sample (n=6 for each level) on the same day.
The inter-assay (between-day) precision and accuracy were deter-
mined by analysing each QC sample (in duplicate) on six different
days. Intra-assay and inter-assay precision were expressed as the
percentage RSD of the measured concentrations of the QC samples.
Accuracy was expressed as the percentage relative error (R.E.%) for
eachQC level by comparing thenominal concentration and the esti-
mated concentration determined after extraction. For acceptable
intra- and inter-assay values, the precision should not exceed 15%
except at the LLOQ, where it should not exceed ±15%. The accuracy
should bewithin±15% of the nominal concentrations, except at the
LLOQ, where R.E.% should be ≤20% [41]. The correlation coefﬁcient
of the calibration curve was set at 0.99 or better.
2.7.5. Extraction recovery
The extraction recovery of ciproﬂoxacin fromplasmawas deter-
mined by assaying aliquots (200L) of drug-free plasma samples
spiked with low and high ciproﬂoxacin concentrations (1.0 and
3.0g/mL) and IS (200ng). In another set of test tubes, equiva-
lent ciproﬂoxacin concentrations were spiked into the extraction
solvent. The samples were extracted according to the procedure
described in Section 2.6. The extraction recovery was determined
by comparing the peak area ratios (ciproﬂoxacin/IS) from a given
concentrationof ciproﬂoxacin spiked inblankplasmawith thepeak
area ratios obtained for the same concentration of ciproﬂoxacin
spiked in the extraction solvent. Percentage recovery = (peak area
of ciproﬂoxacin concentration extracted from spiked plasma/peak
area of ciproﬂoxacin concentration directly added to extraction
solvent)×100]. The recovery of the IS was evaluated at the con-
centration used in sample analysis (200ng).
2.7.6. Stability
Stability experiments should reﬂect the conditions likely to be
encountered during sample transfer, handling and analysis. In our
setting, clinical samples from patients are stored at −20 ◦C imme-
diately after collection, before being transferred (on dry ice) to a
−80 ◦C freezer for longer term storage. The samples are thawed
and analyzed immediately. The stability of ciproﬂoxacin in human
plasma was evaluated using spiked plasma ciproﬂoxacin concen-
trations at low (1.0g/mL) and high (3.5g/mL), which were
prepared from a fresh stock solution. An aliquot of each sample
was analyzed immediately. The other aliquots were stored at var-
ious temperatures (2–8 ◦C, −15 ◦C to −25 ◦C and −70 ◦C to −90 ◦C)
for 7and30days. Ciproﬂoxacin concentrationsweredeterminedon
day 7 and day 30. The results were compared with those obtained
on the ﬁrst day of the stability testing. The percentage concentra-
tion deviation was calculated. For acceptance criterion of stability,
the deviation of themeasured concentrations of the stored samples
compared to the freshly prepared samples should be within ±15%.
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.8. Application of the method to population pharmacokinetic
tudy in malnourished children
The validated HPLC method was applied to evaluate the pop-
lation pharmacokinetics of ciproﬂoxacin in 52 Kenyan children
ith severe malnutrition. The Kenya Medical Research Institute
KEMRI)/National Ethical Review Committee approved the study
hich was conducted in accordance ICH/Good Clinical Practice
GCP) guidelines [42]. Children were recruited after obtaining
nformed consent from the parents/guardians of the children. All
hildren received the standard medical treatment for severe mal-
utrition. Children who were recruited into the study were given
ral ciproﬂoxacin (10mg/kg every 12h for 24h). Four venous blood
amples (0.75mL) were collected into lithium heparinized tubes
efore drug administration (pre-dose), and at pre-speciﬁed times
ver an initial 24-h period following drug administration. The
lood samples were immediately centrifuged (2500 rpm; 10min)
o separate plasma which was stored frozen at −80 ◦C until ana-
yzed. In this manuscript, we report the plasma ciproﬂoxacin
oncentration–time proﬁles for three patients.
. Results and discussion
.1. Optimization of HPLC ﬂuorescence chromatographic
onditions
The chromatographic conditions were optimized through
everal iterations of the method to achieve good resolution,
ymmetric peak shapes for both ciproﬂoxacin and IS, and short
un time (<10min) while achieving selectivity and sensitivity. In
reliminary experiments, several types ofHPLC columnswere eval-
ated, including Phenomenex Synergi Polar RP (150mm×4.6mm;
m), Luna C18(2) (150mm×4.6mm, 5m), and Gemini C18
150mm×4.6mm, 5m). However, the retention times of
iproﬂoxacin and IS were longer and the peak shape was unsat-
sfactory. After careful comparison, a Phenomenex Synergi Max RP
150mm×4.6mm; 4m) columnwas ﬁnally usedwith a ﬂow rate
f 1mL/min,whichproduced goodpeak shapes and alloweda chro-
atographic run time of les than 10min.
Several factors affect the chromatographic analysis of
iproﬂoxacin in biological matrices. The composition of the
tock solution is critical, since dissolving ciproﬂoxacin in acidiﬁed
ethanol results in esteriﬁcation of the carboxylic acid group [43].
n the present study, we used 0.2M HCl to prepare a standard
tock solution of ciproﬂoxacin, since the drug is poorly soluble
n water. The pH of the mobile phase is very critical because the
K value of ciproﬂoxacin is affected by the composition of the
obile phase. In the present study, the pH of the mobile phase was
djusted to 3.0 with triethyamine. Like most ﬂuoroquinolones,
iproﬂoxacin exhibits strong spontaneous ﬂuorescence properties
ithout derivatization, which allows adequate sensitivity [44]. The
xcitation spectrumof ciproﬂoxacin shows twomaxima at 279 and
26nm, while an emission spectrum shows an optimal response
ith emission at 442nm [37]. In this study, the ﬂuorescence
etector was set at excitation and emission wavelengths of 278 at
50nm, respectively.
.2. Extraction procedure
Plasma is a complex biological matrix which can hamper detec-
ion of drugs and their metabolites. Sample clean-up procedure is
herefore often needed to remove plasma proteins and potential
nterferences by other endogenous compounds prior to HPLC anal-
sis. The sensitivity and selectivity of the method can be limited
y the clean-up procedures. Ciproﬂoxacin is a polar, water-soluble
nd amphoteric compound,whichmakes it difﬁcult to extract fromgr. B 879 (2011) 146–152 149
plasmaby liquid–liquid extraction (LLE) and solid-phase extraction
(SPE) procedures. To avoid loss of analyte due to clean-up proce-
dures and increase recovery of analyte, thenumber of cleanup steps
in a sample preparation procedure should be kept to a minimum.
Protein precipitation is commonly used for fast sample clean-up
anddisruptingprotein–drugbinding. Various organic solvents (e.g.,
acetonitrile and methanol) and acids (e.g. perchloric acid, phos-
phoric acid, triﬂuoroacetic acid) were used as protein precipitants
in previously published methods [17,21,22,31,32,37]. Protein pre-
cipitation with acetonitrile or methanol is a simple procedure. In
the present method, acetonitrile was chosen as the protein pre-
cipitant because it resulted in good signal intensities and high
extraction recoveries for both ciproﬂoxacin and IS, and relatively
clean chromatograms under ﬂuorescence detection. Compared to
other sample preparation methods, the reported method is simple,
thus reducing the time required sample clean-up. The IS corrected
for variation in the extraction recovery of the analyte during the
sample clean-up steps. Although evaporation and reconstitution
steps are included, the sample clean-up method remains a simple
method and allows high throughput analysis necessary for phar-
macokinetic studies.
Another advantage is the speed of the assaywhich ismore rapid
than most other methods that require long run chromatographic
times (>10min). Finally, the sample preparation procedure is based
ona simpleproteinprecipitation step, therebyeliminating theneed
of performingmultiple steps involved in SPE and LLEprocedures for
other methods. The HPLC separation procedure is simple and can
be easily reproduced because it has been performed under isocratic
conditions, using a simple mobile phase composition, comprising
orthophosphoric acid/methanol/acetonitrile and triethylamine.
3.3. Chromatography
Under the described chromatographic conditions, ciproﬂoxacin
was well separated from the IS, with retention times of about
3.6min and 7.0min, respectively (Fig. 1). The chromatographic
run time for each sample was about 8min. Fig. 1b showed chro-
matograms of plasma extracts from pre-dose (B) and 3h (C) after
administration of oral ciproﬂoxacin (10mg/kg) to a child with
severe malnutrition.
3.4. Method validation
3.4.1. Assay selectivity
The selectivity of themethodwas tested by comparing the chro-
matograms of six different batches of blank human plasma. Fig. 1a
shows a representative chromatogram of a blank plasma sam-
ple. There was no chromatographic interference from endogenous
compounds at the retention times of ciproﬂoxacin and IS (Fig. 1a
and b). The chromatographic peaks were well resolved to base-
line.We investigatedother co-administereddrugs in spikedplasma
which were not found to interfere with the assay.
3.4.2. Linearity of calibration curves
The linearity of the calibration curve for ciproﬂoxacin in spiked
drug-free plasma over the ciproﬂoxacin concentration range of
0.02−4.0g/mL was evaluated. Calibration curves consisting of
nine concentration values (0.02, 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 3.0 and
4.0g/mL) of ciproﬂoxacin spiked in human plasma were con-
structed. The calibration curves for ciproﬂoxacin were linear over
the range of 0.02–4.0g/mL. The mean linear regression equation
of the calibration curves (n=13) was: Y=1.149X+0.034; where Y
represents the peak area ratio (ciproﬂoxacin/IS), and X represents
the plasma concentration of ciproﬂoxacin (g/mL). The mean cor-
relation coefﬁcient (r2) for the ciproﬂoxacin calibration curves was
0.998.
150 S.N. Muchohi et al. / J. Chromatogr. B 879 (2011) 146–152
Fig. 1. (a) Representative chromatograms of (A) un-extracted (direct injection) ciproﬂoxacin (100ng) and saraﬂoxacin (internal standard, IS; 100ng), (B) extracted aliquot
(200L) of drug-free human plasma spiked with IS (200ng) and (C) extracted aliquot (200L) of drug-free human plasma spiked with ciproﬂoxacin (0.05g/mL) and
IS (200ng). Peaks: 1 = ciproﬂoxacin; 2 = saraﬂoxacin (IS). (b) Representative chromatograms of extracted aliquot (200L) of (A) plasma sample spiked with ciproﬂoxacin
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.7g/mL. Peaks: 1 = ciproﬂoxacin; 2 = saraﬂoxacin (IS).
.4.3. Limit of detection (LOD) and lower limit of quantiﬁcation
LLOQ)
The assay LOD was deﬁned as the lowest concentration of ana-
yte that produced a chromatographic peak distinguishable from
hebackgroundnoise (signal-to-noise (S/N) ratio 3:1). The LODwas
0ng/mL,while LLOQwas 20ng/mL. In some of the publishedHPLC
ethods, relatively large volumes of plasma (500–1000L) were
sed for sample preparation [17,18,32,35,39] so are less suitable for
aediatric studies. In the present study only 200L of plasma was
eeded for the assay, so is suitable for population pharmacokinetic
tudies involving serial drug concentration measurements..4.4. Precision and accuracy
Intra-assay, inter-assay precision and accuracy data are sum-
arized (Table 1). The intra-assay RSDs at 0.2, 1.8 and 16g/mL of
iproﬂoxacin were 7.7%, 4.3% and 2.8% (n=6 in all cases), respec-
able 1
ntra-assay and inter-assay precision and accuracy of the assay for ciproﬂoxacin in plasm
alculated as [(estimated concentration−nominal concentration)/nominal concentration
Quality control (QC) sample Nominal concentration
(g/mL)
No. of replicates (n)
Intra-assay
LQC 0.2 6
MQC 1.8 6
HQC 3.6 6
Inter-assay
LQC 0.2 6
MQC 1.8 6
HQC 3.6 6B) a pre-dose plasma sample obtained following administration of an oral dose of
ed IS (200ng), (C) a plasma sample collected after 3h following administration of
spiked with IS (200ng). The estimated plasma concentration of ciproﬂoxacin was
tively. The inter-assayRSDs for the above concentrationswere5.7%,
3.6% and 4.9% (n=6 in all cases), respectively. Intra-assay and inter-
assay accuracy ranged from 93% to 105% (Table 1). These results
indicated that the validated assay was precise, accurate and repro-
ducible.
3.4.5. Extraction recovery
The mean (±SD) percentage extraction recoveries of
ciproﬂoxacin at the three ciproﬂoxacin concentrations (0.08,
1.8 and 3.6g/mL) were 78.1±12.5% (n=4), 83.5±5.2% and
77.7±2.0%, respectively (n=8 in both cases). The mean (±SD)
extraction recovery for IS was 94.5±7.9% (n=15) (Table 2). The
use of an IS in the extraction procedure is crucial to compen-
sate for variability in extraction efﬁciency. In the present study,
saraﬂoxacin was chosen as the IS because ciproﬂoxacin and
saraﬂoxacin are structural analogues, with similar chemical char-
a. SD= standard deviation; RSD= relative standard deviation; R.E. = residue error,
].
Mean (SD) estimated
concentration (g/mL)
Precision (%RSD) Accuracy (%R.E.)
1.96 (0.02) 7.70 97.8
1.89 (0.08) 4.33 104.7
3.69 (0.11) 2.83 102.6
0.21 (0.01) 5.72 105.0
1.80 (0.07) 3.58 100.2
3.36 (0.16) 4.87 93.3
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Table 2
Extraction recovery for ciproﬂoxacin and saraﬂoxacin (IS) from spiked plasma.
Analyte Nominal concentration
(g/mL)
No. of
replicates (n)
% Recovery (mean± SD) (%RSD)
Ciproﬂoxacin 0.08 5 72.8 ± 12.5 17.2
1.8 8 83.5 ± 5.2 6.2
3.6 8 77.7 ± 2.0 2.5
Saraﬂoxacin (IS) 200ng 15 94.5 ± 7.9 8.3
Table 3
Stability of ciproﬂoxacin at various storage temperatures (2–8 ◦C, −15 ◦C to −25 ◦C and −70 ◦C to −90 ◦C).
Storage duration (days) Ciproﬂoxacin
concentration (g/mL)
Storage stability (%)
2–8 ◦C −15 ◦C to −25 ◦C −70 ◦C to −90 ◦C
0 1.0 100.0 100.0 100.0
7 1.0 98.3 83.7 99.1
a
r
w
g
o
w
o
h
3
p
s
m
3
s
m
i
t
2
s
n
F
l
t30 1.0
0 3.0
7 3.0
30 3.0
cteristics and properties. Saraﬂoxacin exhibits good ﬂuorescence
esponse at the excitation wavelength (278nm) and emission
avelength (450nm). It also displayed appropriate chromato-
raphic retention with its peak sufﬁciently separated from that
f ciproﬂoxacin, and relatively high extraction recovery. It is
idely used in veterinary medicine, and therefore, the possibility
f encountering interference from therapeutic concentrations in
umans is minimal.
.4.6. Stability
Stability data for ciproﬂoxacin in spiked drug-free human
lasma are summarized in Table 3. Ciproﬂoxacin was stable in
piked plasma when stored for one week at 2–8 ◦C, and for one
onth when stored at −15 ◦C to −20 ◦C and −80 ◦C to −90 ◦C.
.5. Application of the method to population pharmacokinetic
tudy in malnourished children
To demonstrate its utility in a pharmacokinetic study, the
ethodwas applied tomeasure the concentrations of ciproﬂoxacinn plasma samples obtained from children with severe malnutri-
ion who were given oral ciproﬂoxacin (10mg/kg 12 hourly over
4h). A representative chromatogram from an extracted plasma
ample from a child is shown in Fig. 1b(B) and (C). There were
o interfering endogenous peaks. The semi-logarithmic plasma
Time (hours)
0 2 4 6 8 10 12
)L
m/g
μ( noitartnecnoc a
msalp nicaxolforpiC 0.1
1
10
Paent A
Paent C
Paent B
ig. 2. Semi-logarithmic plasma concentration–time proﬁles of ciproﬂoxacin fol-
owing administration of an oral dose of ciproﬂoxacin (10mg/kg every 12h for 24h)
o three children with severe malnutrition.92.6 95.4 103.3
100.0 100.0 100.0
73.2 76.6 80.0
77.6 84.9 84.3
ciproﬂoxacin concentration–time proﬁles of three patients are
shown in Fig. 2. Oral absorption of ciproﬂoxacin was variable.
Peak plasma ciproﬂoxacin concentrations ranging from 1.3 to
2.0g/mL were achieved within 1–5h after oral administration
of ciproﬂoxacin (10mg/kg every 12h) in children with severe
malnutrition. In this group of children, ciproﬂoxacin was rapidly
eliminated from the body, reaching undetectable levelswithin 12h
following drug administration (Fig. 2).
4. Conclusion
This paper describes a simple, rapid and selective, sensitive and
reproducible method for the determination of ciproﬂoxacin con-
centrations inhumanplasmausingHPLCcoupledwithﬂuorescence
detection. The method offers several advantages for assaying the
drug in low technology laboratories including ease, cost, good pre-
cision and accuracywith high sensitivity and selectivity. Moreover,
themethod requires only a small volume (200L) of plasma,which
makes it suitable for studying the pharmacokinetics in young chil-
dren. The sensitivity and simplicity of themethodmakes it suitable
for routine therapeutic drug monitoring or clinical pharmacoki-
netic studies of ciproﬂoxacin. This assay method was successfully
applied for a population pharmacokinetic study of ciproﬂoxacin
following oral administration in children with severe malnutrition.
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